The roGFP1-iL and roGFP2-iL only differ in the S65T substitution introducing an additional methyl group in roGFP2
Let us help you become your best self
This does not invalidate the findings, but it means the evidence base is not yet at the level of FDA-approved pharmaceuticals
Here's a more detailed look: Key aspects of GHK-Cu: Natural Occurrence: GHK-Cu is a naturally occurring peptide in human serum, but its levels decrease with age
HUBERMAN: To the hypothalamus, from the hypothalamus to the pituitary, and then the melanocyte-stimulating hormone is then released into the bloodstream, can travel to the melanocytes and cause pigmentation of the skin
Systemic effects that have been reported in trials, or that are mechanistically expected from elevated GH and IGF-1, include: Water retention and mild edema , particularly in the hands, ankles, and face Tingling, numbness, or 'pins and needles' (paresthesia) , sometimes linked to fluid pressure on nerves Headache and facial flushing , often shortly after administration Joint aches or stiffness (arthralgia) Transient changes in blood glucose due to GH's counter-regulatory effect on insulin Fatigue, dizziness, or a feeling of light-headedness in some individuals It is important to be candid about the limits of this evidence
